Is NCT05610852 recruiting in Cleveland, OH?

Yes, NCT05610852 is currently recruiting participants at its Cleveland, OH location. This prostate adenocarcinoma clinical trial is actively enrolling qualified participants.

How do I join the prostate adenocarcinoma clinical trial in Cleveland?

To join this clinical trial in Cleveland, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Cleveland clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Prostate Adenocarcinoma Clinical Trial in Cleveland, OH

About This Prostate Adenocarcinoma Study in Cleveland

This study aims to compare the novel single-port robotic partial prostatectomy to High-intensity focused ultrasound (HIFU) in patients with low to intermediate risk localized prostate cancer. These interventions have become acceptable focal therapies prevalent with beneficial oncologic outcomes and therefore need to be examined further.

Sponsor: Case Comprehensive Cancer Center

Who Can Participate

Inclusion Criteria

Subjects must have histologically or cytologically: Biopsy-confirmed prostate cancer, stage T1a, T2a, T2b, or T2c prostate cancer using MRI staging, with a region of interest (ROI) PIRADs grade 3 or greater, Serum PSA 10 ng/ml or less, Region of interest on MRI of grade 3 or greater

The MRI performed must include at least:

A T2-weighted sequence in sections ≤ 4 mm, centered on the prostate and seminal vesicles, at least in the axial plane. Alternatively, a 3D T2-weighted sequence can be realized,

A diffusion sequence of ≤ 4 mm slice in the axial plane. An ADC card will be provided and calculated from at least two values of b, the maximum value of b being ≥ 600 s / mm2,

A dynamic sequence after gadolinium injection. It will be a sequence of echo T1-weighted gradient of slice ≤ 4 mm, centered on the prostate and seminal vesicles in the axial plane, with or without fat saturation. A first series will be performed without contrast injection, and will be repeated iteratively for the arrival of a bolus of gadolinium chelates. The time resolution (that is to say, the acquisition time of one dynamic series will be ≤ 20 seconds). The number of chained dynamic series is calculated so that the total length of the dynamic acquisition be at least 3 minutes

A total dose of 0.1 mmol / kg of gadolinium chelate will be injected at a rate of 3-4 mL / s by using an automatic injector, in a vein of the hand of the forearm or elbow.

If necessary, subtracted images are calculated

Clinically significant prostate cancer defined as Gleason score 3+4 or less in any core

Biopsies for preoperative diagnosis of prostate cancer will have included: At least 12 randomized samples (2 samples per sextant), At least two targeted sampling on each target score MRI ESUR ≥ 3/5

Life expectancy greater than 10 years.

Age \>18 years.

Subjects must have the ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria

Patients with any prior extensive pelvic surgery, pelvic fractures, hemorrhoid, fissure surgery, cardiac pacemaker, or metal prosthesis

Prior treatment for prostate cancer such as radiotherapy, focal or hormonal therapy

Uncorrected coagulopathy or history of Latex allergy

Active soft tissue or urinary infection, indwelling Foley catheter or severe irritative or obstructive symptoms

Poor surgical risk (defined as American Society of Anesthesiology score \> 3).

Any condition or history of illness or surgery that, in the opinion of the investigator, might confound the results of the study or pose additional risk to the patient (e.g. significant cardiovascular conditions that significantly affect the life expectancy, chronic opiate use, pain syndrome, or drug abuse.)

Prostate size larger than 80 grams.

Subjects with prostatic Calcification (\>0.5 cc) close to the area to be treated.

Subjects with extraprostatic extension or cribriform pattern on biopsy.

Subjectes with sexual dysfunction defined as SHIM score \< 17

Subjects with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Cleveland?

Yes, this clinical trial (NCT05610852) has an active research site in Cleveland, OH that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Prostate Adenocarcinoma Treatment Options in Cleveland, OH

If you're searching for prostate adenocarcinoma treatment options in Cleveland, OH, this clinical trial (NCT05610852) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Cleveland research site is actively enrolling participants for this clinical trial. You'll receive care from experienced prostate adenocarcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all prostate adenocarcinoma clinical trials near you to find additional studies recruiting in your area.

Prostate Adenocarcinoma Clinical Trial in Cleveland, OH

Expert Care in Cleveland

IRB Approved

No-Cost Care

Apply for This Cleveland Location

Why Participate?

Simple Process